Who
Hamid Khoja
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, FibroBiologics.
In numbers
- Trades disclosed
- 12
- Buys
- 3
- Sells
- 0
- Bought
- $59K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Aug 2024
- Last trade
- 15 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Code A | $500K298,508 at $1.68 | filing |
| 15 Sep 2026filed 15 Sep 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —298,508 | filing |
| 15 Sep 2026filed 15 Sep 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —298,508 | filing |
| 15 Sep 2026filed 15 Sep 2026 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Code A | $501K298,508 at $1.68 | filing |
| 4 May 2026filed 4 May 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,607 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,607 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Bought | $11K30,000 at $0.38 | filing |
| 4 Mar 2026filed 5 Mar 2026 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Bought | $11K30,000 at $0.38 | filing |
| 27 May 2025filed 27 May 2025 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Bought | $17K20,000 at $0.84 | filing |
| 26 Mar 2025filed 28 Mar 2025 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —189,000 at $0.00 | filing |
| 27 Dec 2024filed 30 Dec 2024 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —176,200 at $0.00 | filing |
| 12 Aug 2024filed 12 Aug 2024 | FBLG FibroBiologicsBiotechnology | SEC FORM 4 Bought | $19K10,000 at $1.90 | filing |
News
No headline names them, or the companies they trade most, lately.